We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

S-1, Oxaliplatin, and Irinotecan for Advanced Gastrointestinal Cancer

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01693445
First Posted: September 26, 2012
Last Update Posted: February 19, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
Jeil Pharmaceutical Co., Ltd.
CJ HealthCare Corporation
Pfizer
Handok Pharmaceuticals Co., Ltd.
Information provided by (Responsible Party):
Hallym University Medical Center
  Purpose
This study will attempt to determine the feasibility of combination of Oxaliplatin, Irinotecan, and S-1, the maximum tolerated dose and the recommended doses of the agents used, and to preliminarily evaluate the antitumor activity in untreated patients with advanced gastrointestinal cancer.

Condition Intervention Phase
Gastrointestinal Neoplasms Drug: OIS (Oxaliplatin, Irinotecan, S-1) Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Dose Finding Study of S-1, Oxaliplatin, and Irinotecan Combination Chemotherapy for Patients With Inoperable Advanced or Metastatic Gastrointestinal Cancers

Resource links provided by NLM:


Further study details as provided by Hallym University Medical Center:

Primary Outcome Measures:
  • maximum tolerated dose [ Time Frame: 6 months ]

Secondary Outcome Measures:
  • toxicity profiles [ Time Frame: 6 months ]
  • overall response rate [ Time Frame: 6 months ]
  • progression free survival [ Time Frame: 6 months ]
  • overall survival [ Time Frame: 6 months ]
  • disease control rate [ Time Frame: 6 months ]

Enrollment: 22
Study Start Date: June 2012
Study Completion Date: August 2014
Primary Completion Date: February 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: OIS (Oxaliplatin, Irinotecan, S-1)

Dose level 1 treatment will be delivered as a 2-week cycle as bellows;

  1. Oxaliplatin 85 mg/m²IV on day 1
  2. Irinotecan 120 mg/m² IV on day 1
  3. S-1 60 mg/m2/day PO on day 1-7 Dose escalation will be continued until more than one-third of the patients in a given cohort show dose limiting toxicities (DLT) during treatment cycle 1. If at least 2 patients are observed to have DLT, this dose level is defined as the maximum tolerated dose (MTD). If exactly 1 of the 3 patients treated show DLT, 3 additional patients are treated at the current dose level.
Drug: OIS (Oxaliplatin, Irinotecan, S-1)

Dose level 1 treatment will be delivered as a 2-week cycle as bellows;

  1. Oxaliplatin 85 mg/m²IV on day 1
  2. Irinotecan 120 mg/m² IV on day 1
  3. S-1 60 mg/m2/day PO on day 1-7

Dose escalation will be continued until more than one-third of the patients in a given cohort show dose limiting toxicities (DLT) during treatment cycle 1. If at least 2 patients are observed to have DLT, this dose level is defined as the maximum tolerated dose (MTD). If exactly 1 of the 3 patients treated show DLT, 3 additional patients are treated at the current dose level.

Other Names:
  • Kabioxaliplatin
  • Campto
  • TS-1

Detailed Description:

Oxaliplatin or irinotecan has shown a considerable anti-tumor activity, when used in combination with 5-fluorouracil (5-FU) in patients with gastrointestinal (GI) cancer. Oxaliplatin, irinotecan, and 5-FU have different mechanisms of actions and do not share the toxicity profiles. Since they have a synergistic effect, many clinical trials have been conducted recently to evaluate the efficacy of triplet combination consisting of oxaliplatin, irinotecan, and 5-FU, and demonstrated that the triple combination regimen was effective and resulted in survival benefits with favorable toxicity profiles.

S-1 and capecitabine are novel oral fluoropyrimidines and different phase III trials have shown that these oral agents are at least as active and effective as 5-FU with a superior safety profile.

Biweekly triple combination of S-1 with oxaliplatin and irinotecan (OIS) is an interesting alternative to increase convenience and to simply the treatment delivery.

In the present study, we attempt to determine the feasibility of OIS combination, the maximum tolerated dose and the recommended doses of the agents used, and to preliminarily evaluate the antitumor activity in untreated patients with advanced gastrointestinal cancer.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically proven recurrent or metastatic adenocarcinoma of the gastrointestinal tract
  • Minimum age of 18 years
  • ECOG Performance status 0-2
  • Life expectancy >3 months
  • Presence of measurable or evaluable disease by RECIST
  • Prior adjuvant chemotherapy without S-1, oxaliplatin and irinotecan is allowed if more than 4 weeks elapsed since completion of chemotherapy.
  • More than 4 weeks since completion of prior radiotherapy (measurable or evaluable lesions should be outside the radiation field)
  • Adequate organ functions
  • Patients must sign an informed consent indicating that they are aware of the investigational nature of the study in keeping with the policy of the hospital

Exclusion Criteria:

  • Patients treated previously with S-1, oxaliplatin, or irinotecan as adjuvant chemotherapy.
  • Patients with CNS metastases or carcinomatous leptomeningitis or neurologic disease.
  • Patients with active infection, severe heart disease, uncontrollable hypertension or diabetes mellitus, myocardial infarction during the preceding 6 months, pregnancy, or breast feeding
  • Any previous or concurrent malignancy other than non-melanoma skin cancer or in situ cancer of uterine cervix
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01693445


Locations
Korea, Republic of
Hallym University Medical Center
Anyang, Korea, Republic of
Sponsors and Collaborators
Hallym University Medical Center
Jeil Pharmaceutical Co., Ltd.
CJ HealthCare Corporation
Pfizer
Handok Pharmaceuticals Co., Ltd.
Investigators
Principal Investigator: Dae Young Zang, MD, PhD Hallym University Medical Center
  More Information

Responsible Party: Hallym University Medical Center
ClinicalTrials.gov Identifier: NCT01693445     History of Changes
Other Study ID Numbers: HMC-HO-GI-1203
First Submitted: September 20, 2012
First Posted: September 26, 2012
Last Update Posted: February 19, 2016
Last Verified: September 2012
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Keywords provided by Hallym University Medical Center:
Gastrointestinal neoplasms
Oxaliplatin
Irinotecan
S-1

Additional relevant MeSH terms:
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Oxaliplatin
Irinotecan
Camptothecin
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action